{"id":5105,"name":"Adjuvant Capital","slug":"adjuvant-capital","website":"https://adjuvantcapital.com","hqGeo":"New York, NY","stageFocus":["Seed","Pre-Seed"],"sectorTags":["Healthcare"],"excludedSectors":[],"checkSizeMin":250000,"checkSizeMax":2500000,"thesisSummary":"Invests in innovative technologies and therapies for major global health challenges, including oncology and genetic therapies.","thesisNarrative":null,"logoUrl":null,"aumUsd":300000000,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"LimmaTech Biologics","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2023,"description":"Vaccine development company working to halt AMR and STI infections.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Curevo Vaccine","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2022,"description":"Next-generation subunit vaccines, initially targeting varicella and shingles.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Memo Therapeutics","companyUrl":null,"stage":null,"sector":"Therapeutic","investmentYear":2022,"description":"Antibody discovery platform, initially targeting Nipah virus, SARS-CoV-2, CMV and BKV.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Antiva Biosciences","companyUrl":null,"stage":null,"sector":"Therapeutic","investmentYear":2021,"description":"Novel non-surgical therapeutic candidate to treat pre-cancerous cervical lesions caused by HPV.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Pulmocide","companyUrl":null,"stage":null,"sector":"Inhaled Therapeutic","investmentYear":2021,"description":"Novel therapies for patients suffering from serious acute and chronic respiratory diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Excision BioTherapeutics","companyUrl":null,"stage":null,"sector":"Therapeutic","investmentYear":2021,"description":"CRISPR-based therapies for chronic viral infectious diseases such as HIV and hepatitis B.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"LakeShore Biopharma","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2020,"description":"LakeShore is scaling up undersupplied global health vaccines and developing new biologics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ChromaCode","companyUrl":null,"stage":null,"sector":"Platform","investmentYear":2020,"description":"ChromaCode's HD-PCR technology enhances multiplexing capabilities on existing hardware.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Codagenix","companyUrl":null,"stage":null,"sector":"Platform","investmentYear":2020,"description":"Codagenix uses emerging computational and synthetic biology tools to rationally design vaccines.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"54gene","companyUrl":null,"stage":null,"sector":"Platform","investmentYear":2020,"description":"54gene is using African genetic data to drive discoveries in drug and vaccine development.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Frontier Nutrition","companyUrl":null,"stage":null,"sector":"Lipid-Based Nutritional Supplements (LNS)","investmentYear":2020,"description":"Fortified snacks to address maternal and childhood malnutrition in Bangladesh.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"VitriVax","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2020,"description":"Thermostability and pulsatile dosing technology for vaccines and other sensitive biologics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"MinervaX","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2020,"description":"Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Evofem","companyUrl":null,"stage":null,"sector":"Contraceptive","investmentYear":2020,"description":"Woman-controlled, non-hormonal contraceptive.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Univercells","companyUrl":null,"stage":null,"sector":"Process Innovation","investmentYear":2020,"description":"Univercells uses advanced manufacturing technologies to make 'Biologics for all.'","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"X-Vax","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2019,"description":"X-Vax is developing a vaccine to beat herpes.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"AN2 Therapeutics","companyUrl":null,"stage":null,"sector":"Small Molecule","investmentYear":2019,"description":"AN2 is developing novel, broad-spectrum therapeutics for infectious diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Themis","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2019,"description":"Themis is developing novel vaccines for high burden infectious diseases and oncology applications.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"InDevR","companyUrl":null,"stage":null,"sector":"Process Innovation","investmentYear":2019,"description":"InDevR is developing advanced characterization assays for biologics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Tyra Biosciences","companyUrl":null,"stage":null,"sector":"Oncology","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":5,"partners":[{"id":14979,"name":"Kabeer Aziz","title":"Partner","seniority":null,"focusTags":["global health technology commercialization","emerging markets","public health innovation"],"linkedinUrl":"https://www.linkedin.com/in/kaziz107","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14978,"name":"Glenn Rockman","title":"Managing Partner","seniority":null,"focusTags":["infectious diseases","maternal & child health","neglected tropical diseases","global health technologies"],"linkedinUrl":"https://www.linkedin.com/in/grockman","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14981,"name":"Philippe Dro","title":"Partner","seniority":null,"focusTags":["biopharma","medical devices","vaccine development","European investments in health technologies"],"linkedinUrl":"https://www.linkedin.com/in/philippe-dro","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14983,"name":"Gerard Cunningham","title":"Operating Partner","seniority":null,"focusTags":["operational execution","scale-up of global health technologies","manufacturing / supply chain","public health delivery"],"linkedinUrl":"https://www.linkedin.com/in/gerard-cunningham-8404415","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14982,"name":"Kate Antrobus","title":"Venture Partner","seniority":null,"focusTags":["industrialization models","portfolio strategy","access in sub-Saharan Africa","blended finance in global health"],"linkedinUrl":"https://www.linkedin.com/in/kate-antrobus-cfa-43b886100","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":2023,"investmentsThisYear":0},"activityItems":[{"kind":"news","title":"Adjuvant Capital announces $300m venture fund to improve public health","url":"https://africaglobalfunds.com/news/private-equity/fundraising/adjuvant-announces-300m-venture-fund-to-improve-public-health/","source":"Africa Global Funds","occurredAt":"2026-10-26T00:00:00.000Z"},{"kind":"news","title":"Adjuvant Capital Announces $300 Million Venture Fund Designed to Improve Global Public Health","url":"https://sif.gatesfoundation.org/portfolio/?_focus_area=191","source":"Strategic Investment Fund / Gates Foundation","occurredAt":"2026-10-26T00:00:00.000Z"},{"kind":"news","title":"Operating Principles for Impact Management 2026 Disclosure Statement","url":"https://adjuvantcapital.com/news/2026-10-14-operating-principles-for-impact-management-2026-disclosure-statement/","source":"Adjuvant Capital","occurredAt":"2026-10-14T00:00:00.000Z"},{"kind":"news","title":"Adjuvant Capital Publicly Shares its 2025 Annual Report","url":"https://adjuvantcapital.com/news/2026-10-14-adjuvant-capital-publicly-shares-its-2025-annual-report/","source":"Adjuvant Capital","occurredAt":"2026-10-14T00:00:00.000Z"},{"kind":"news","title":"Adjuvant Capital Included in ImpactAssets 50 List for 2026","url":"https://adjuvantcapital.com/news/2026-03-10-adjuvant-capital-included-in-impactassets-50-list-for-2026/","source":"Adjuvant Capital","occurredAt":"2026-03-10T00:00:00.000Z"}],"contentUpdatedAt":"2026-11-03T01:09:12.032Z","investorType":"vc","preferredApproach":"warm intro preferred","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":11323,"name":"Mountain Pine Capital","slug":"mountain-pine-capital","logoUrl":null,"website":"https://mountainpineholdings.com/","stageFocus":["Seed"],"sectorTags":["Consumer","Healthcare","Real Estate"],"hqGeo":"Salt Lake City, UT"},{"id":1621,"name":"Canary","slug":"canary","logoUrl":null,"website":"https://www.canary.capital/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Fintech","AI / ML","SaaS","Healthcare","Enterprise"],"hqGeo":"São Paulo, Brazil"},{"id":12955,"name":"Jovono","slug":"jovono","logoUrl":null,"website":"https://jovono.com","stageFocus":["Seed","Series A"],"sectorTags":["Climate / Energy","Fintech","Consumer","SaaS","Healthcare"],"hqGeo":"Los Angeles, CA"},{"id":12160,"name":"Solid Ventures","slug":"solid-ventures","logoUrl":null,"website":"https://www.solidventures.vc/","stageFocus":["Seed"],"sectorTags":["Fintech","Healthcare","SaaS","Enterprise","Developer Tools","Consumer"],"hqGeo":"Austin, TX"},{"id":13026,"name":"Robin Capital","slug":"robin-capital","logoUrl":null,"website":"https://robincap.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["AI / ML","Fintech","SaaS","Climate / Energy","Healthcare"],"hqGeo":"Berlin, Germany"},{"id":12096,"name":"TeleHealth Ventures","slug":"telehealth-ventures","logoUrl":null,"website":"https://telehealthventures.com","stageFocus":["Seed"],"sectorTags":["Healthcare"],"hqGeo":"Austin, TX"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"},{"slug":"investormatch-mcp-server-claude-chatgpt","title":"Your Investor List Now Lives Inside Claude and ChatGPT"},{"slug":"how-to-find-investors","title":"How to Find Investors: A VC's Playbook for Founders"}],"overviewNarrative":"Adjuvant Capital is a venture capital firm headquartered in New York, NY. The firm invests in innovative technologies and therapies addressing major global health challenges, including oncology and genetic therapies.\n\nAdjuvant Capital focuses on the healthcare, vaccines, and oncology sectors. It typically participates in seed, pre-seed, and early-stage financings with check sizes ranging from $250K to $2.5M. The firm has $300M in assets under management and prefers to be approached via warm introduction.","portfolioNarrative":"Adjuvant Capital has recorded investments in 21 companies. Its earliest recorded investment was made in 2019 and its most recent in 2023.\n\nThe firm's portfolio includes LimmaTech Biologics (2023, vaccine), Curevo Vaccine (2022, vaccine), Memo Therapeutics (2022, therapeutic), Antiva Biosciences (2021, therapeutic), Excision BioTherapeutics (2021, therapeutic), Pulmocide (2021, inhaled therapeutic), 54gene (2020, platform), ChromaCode (2020, platform), Codagenix (2020, platform), Evofem (2020, contraceptive), Frontier Nutrition (2020, lipid-based nutritional supplements), LakeShore Biopharma (2020, vaccine), MinervaX (2020, vaccine), Univercells (2020, process innovation), and VitriVax (2020, vaccine).","seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-05-21T15:18:43.500Z"}